

Cancer Nanotechnology (GRS)

Gordon-Kenan Research Seminar

Science, Engineering, and Translational Research in Cancer Nanotechnology

Dates

June 17-18, 2017

Organizers

Chairs:

Alexander A. Kislukhin & Adriana Avila

Location

Mount Snow
West Dover, VT

Application Deadline

Applications for this meeting must be submitted by **May 20, 2017**. Please apply early, as some meetings become oversubscribed (full) before this deadline. If the meeting is oversubscribed, it will be stated here. *Note:* Applications for oversubscribed meetings will only be considered by the Conference Chair if more seats become available due to cancellations.

GRS Speaker Abstract Deadline: Although applications will be accepted until the date noted above, any applicants who wish to be considered for an oral presentation should submit their application by **March 17, 2017**. Please refer to the application instructions in the *Meeting Description* section below for more details (if available).

Meeting Description

Overview

The Gordon Research Seminar on Cancer Nanotechnology, held for the first time in 2017, will bring together graduate students, post-docs, and other scientists with comparable levels of experience and education to present and exchange new data and cutting edge ideas.

Cancer nanotechnology is a complex discipline that is fueled by the latest advances in basic chemistry and biology. Translating fundamental science and innovative engineering solutions into new clinical options requires a coordinated effort of diverse group of researchers. This unique forum will feature outstanding research by early career scientists across the continuum of cancer research.

Application Instructions

The meeting will feature approximately 10 talks and 2 poster sessions. All attendees are expected to actively participate in the GRS either by giving an oral presentation or presenting a poster. Therefore, all applications must include an abstract.

The Chairs will select speakers from abstracts submitted by **March 17, 2017**. Those applicants who are not chosen for talks and those who apply after the deadline to be considered for an oral presentation will be expected to present a poster. In order to participate, you must submit an application by the date indicated in the *Application Deadline* section above.

Program Format


Saturday

- Introductory Comments: 3:30 pm - 3:45 pm
- Introductory Science Session: 3:45 pm - 4:30 pm
- Poster Session I: 4:30 pm - 6:00 pm
- Dinner: 6:00 pm - 7:00 pm
- Evening Science Session: 7:30 pm - 9:30 pm

Sunday

- Breakfast: 7:30 am - 8:30 am
- Morning Science Session: 9:00 am - 11:00 am
- Poster Session II: 11:00 am - 12:30 pm
- Lunch: 12:30 pm - 1:30 pm
- Concluding Science Session: 1:30 pm - 2:30 pm
- Evaluation Period: 2:30 pm - 3:00 pm
- Program for related GRC begins: 6:00 pm

Related Meeting

 This GRS will be held in conjunction with the "**Cancer Nanotechnology**" **Gordon Research Conference (GRC)**. Those interested in attending both meetings must submit an application for the GRC in addition to an application for the GRS. Refer to the [associated GRC program page](#) for more information.

Contributors



Preliminary Program Outline

An outline of the program components for this GRS is displayed below. The Conference Chair is currently developing their detailed program schedule, which will include the speakers they select from submitted abstracts, in addition to any additional components outlined below. The detailed program will be available by **April 17, 2017**. Please check back for updates.

Keynote Speaker

- **Chad Mirkin** (Northwestern University, USA)
"Spherical Nucleic Acids as a Powerful New Platform to Develop Cancer Vaccines"

Speakers

- *To Be Selected from Submitted Abstracts*

Discussion Leaders

- **Kurt Breitenkamp** (Exponent, Inc., USA)
- **Emily Day** (University of Delaware, USA)
- **Nathan Gianneschi** (University of California, San Diego, USA)

Additional Discussion Leaders May Be Selected from Submitted Abstracts

Funding for this conference was made possible (in part) by 1R13CA213845-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.